Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Lantus (insulin glargine)
Audience – Diabetes healthcare professionals, patients

FDA notified healthcare professionals and patients that it is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus. Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood sugar levels can have both immediate and long-term serious adverse effects.

Read the rest of this entry »

The U.S. Food and Drug Administration is advising diabetes patients who use Lantus, a form of synthetic insulin designed to last longer in the body, to keep using the drug despite a possible link to cancer uncovered by 3 European studies. Manufactured by Sanofi-Aventis of Paris, France, Lantus is a top-selling diabetes drug with sales reaching 2.45 Euros in 2008, about 3.5 billion dollars.

Read the rest of this entry »